- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01049009
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
High blood pressure (hypertension) is called the "silent killer" because many people do not know they have it, and do not know when it is well controlled. Unfortunately, over time uncontrolled hypertension can cause irreversible organ damage that can lead to heart attack, stroke, heart failure, and kidney failure. If a person cannot control their blood pressure with diet and exercise, doctors often prescribe medications to help control the blood pressure. Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension. Our study will investigate whether treatment with nebivolol, as compared to another medication called metoprolol, in African Americans with hypertension will be more effective in protecting blood vessels against the harmful effects of high blood pressure.
Over time high blood pressure causes hardening of the arteries (atherosclerosis) which leads to narrowing of the blood vessels and reduces blood flow to our organs. Arteries also relax and contract naturally, which further changes the blood supply. When arteries are narrowed, exercise can bring on a condition in which the blood supply is inadequate, and this might result in the sensation of pain.
Cells lining our blood vessels produce a variety of substances that normally cause arteries to relax. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). We are trying to determine the nature of these substances in African Americans with high blood pressure and how it is affected by nebivolol and metoprolol. One way to determine this is to inject drugs such as L-NMMA (N(G)-monomethyl-L-arginine) or TEA (tetraethylammonium chloride), which block the production of NO and EDHF respectively, and then study what happens to the blood flow at rest and during exercise. It is our thought that nebivolol, in comparison to metoprolol, will increase the substances that naturally cause arteries to relax and improve blood supply.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or post-menopausal females aged 18-80 years.
- Subjects self-identified as black or African-American.
- Diagnosis of hypertension.
- Patients on current anti-hypertensive therapy that does not include beta blockade should have BP >135/85.
- Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment.
- Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.
Exclusion Criteria:
- Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study
- Inability to return to Emory for follow-up testing
- Age < 21 or >80 years
- Premenopausal females with potential for pregnancy
- Acute infection in previous 2 weeks
- On angiotensin antagonists (ACE inhibitors or ARBs)
- History of substance abuse
- Current neoplasm
- Chronic renal failure [creatinine > 2.5 mg/dL] or liver failure (liver enzymes >2X normal)
- Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months
- Known aortic stenosis, hypertrophic cardiomyopathy.
- Inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nebivolol followed by Metoprolol XL
Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation.
Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
|
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks.
They will then "cross over" to take 10 weeks of the comparator drug.
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks.
They will then "cross over" to take 10 weeks of the comparator drug.
|
|
Active Comparator: Metoprolol XL followed by Nebivolol
Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation.
Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
|
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks.
They will then "cross over" to take 10 weeks of the comparator drug.
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks.
They will then "cross over" to take 10 weeks of the comparator drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks
Time Frame: 12 weeks
|
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise.
Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
|
12 weeks
|
|
Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks
Time Frame: 24 weeks
|
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise.
Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Vascular Diseases
- Cardiovascular Diseases
- Therapeutic Uses
- Nebivolol
- Nitric Oxide
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Adrenergic beta-Antagonists
- Vasodilator Agents
- Sympatholytics
- Vascular Resistance
- Neurotransmitter Agents
- Metoprolol succinate
- Metoprolol
- Cardiovascular Agents
- Endothelium-Dependent Relaxing Factors
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-1 Receptor Agonists
- Nebivolol
- Metoprolol
Other Study ID Numbers
- IRB00017946
Plan for Individual participant data (IPD)
Study Data/Documents
-
Publication
Information identifier: 26285691
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.